

Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

SH-EP

RRID:CVCL_0524

Type: Cell Line

Proper Citation

RRID:CVCL_0524

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0524

Proper Citation: RRID:CVCL_0524

Description: Cell line SH-EP is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Neuroblastoma

Defining Citation: [PMID:1354203](#), [PMID:2535691](#), [PMID:6137586](#), [PMID:24466371](#), [PMID:27517323](#)

Comments: Population: Caucasian.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SH-EP

Synonyms: SHEP

Cross References: BTO:BTO_0005397, EFO:EFO_0006294, MCCL:MCC:0000423, cancercellines:CVCL_0524, Cosmic:1212535, Cosmic:2393640, GEO:GSM1622295, IARC_TP53:23600, Progenetix:CVCL_0524, Wikidata:Q54953212

ID: CVCL_0524

Hierarchy: cvcl_0531

Record Creation Time: 20220427T221540+0000

Record Last Update: 20260904T015649+0000

Ratings and Alerts

No rating or validation information has been found for SH-EP.

No alerts have been found for SH-EP.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Hu A, et al. (2026) Dual targeting of AMRC12 and Malassezia globosa disrupts MYC liquid condensates-driven nuclear pore complex biogenesis in neuroblastoma. *Theranostics*, 16(6), 2866.

Ludwig M, et al. (2026) YAP1 Enhances Mesenchymal-Type Gene Expression in Human Adrenergic-Type Neuroblastoma Cells. *Cancers*, 18(3).

Gautier M, et al. (2026) A regulatory circuitry driving a noradrenergic to mesenchymal transition highlights YAP/TAZ as critical players in neuroblastoma plasticity. *Cell reports*, 45(5), 117351.

Price HE, et al. (2026) Activity of Direct KRAS(G12C) Inhibitors in Preclinical Models of Pediatric Cancer. *Molecular cancer therapeutics*, 25(5), 727.

Chaves GS, et al. (2026) Hypoxia Promotes an Adrenergic to Mesenchymal Transcriptional Program Transition in Neuroblastoma. *Clinical and translational science*, 19(3), e70508.

Hollander JF, et al. (2025) Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma. *Cancer research communications*, 5(1), 167.

Montuori G, et al. (2025) Extrachromosomal DNA-Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers. *Cancer discovery*, 15(10), 2054.

Tiburcio PDB, et al. (2025) PD-L1 Expression is Mediated by microRNA Processing, Wnt/ β -Catenin Signaling, and Chemotherapy in Wilms Tumor. *Pediatric blood & cancer*, 72(9), e31852.

Thombare K, et al. (2024) METTL3/MYCN cooperation drives neural crest differentiation and provides therapeutic vulnerability in neuroblastoma. *The EMBO journal*, 43(24), 6310.

Delhaye L, et al. (2024) Leveraging a self-cleaving peptide for tailored control in proximity labeling proteomics. *Cell reports methods*, 4(7), 100818.

Bate-Eya LT, et al. (2024) Sustained cancer-relevant alternative RNA splicing events driven by PRMT5 in high-risk neuroblastoma. *Molecular oncology*.

Kaufman ME, et al. (2024) Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures. *Cancer research communications*, 4(8), 2255.

Secker C, et al. (2023) The polyphenol EGCG directly targets intracellular amyloid- β aggregates and promotes their lysosomal degradation. *Journal of neurochemistry*.

Jacquier A, et al. (2022) Severe congenital myasthenic syndromes caused by agrin mutations affecting secretion by motoneurons. *Acta neuropathologica*, 144(4), 707.

Tao L, et al. (2022) MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma. *Nature communications*, 13(1), 3728.

Papadopoulos D, et al. (2022) MYCN recruits the nuclear exosome complex to RNA polymerase II to prevent transcription-replication conflicts. *Molecular cell*, 82(1), 159.

Jacquier A, et al. (2022) Expanding the phenotypic variability of MORC2 gene mutations: From Charcot-Marie-Tooth disease to late-onset pure motor neuropathy. *Human mutation*, 43(12), 1898.

Arlt B, et al. (2021) Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma. *International journal of cancer*, 148(5), 1219.

Arlt B, et al. (2021) Inhibiting PHGDH with NCT-503 reroutes glucose-derived carbons into the TCA cycle, independently of its on-target effect. *Journal of enzyme inhibition and medicinal chemistry*, 36(1), 1282.

Chen J, et al. (2021) Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 27(5), 1438.